Abstract

Invasive cancers use pericellular proteolysis to breach the extracellular matrix and basement membrane barriers and invade the surrounding tissue. Proinvasive membrane type-1 matrix metalloproteinase (MT1-MMP) is the primary mediator of proteolytic events on the cancer cell surface. MT1-MMP is synthesized as a zymogen. The latency of MT1-MMP is maintained by its N-terminal inhibitory prodomain. In the course of MT1-MMP activation, the R(108)RKR(111) ↓ Y(112) prodomain sequence is processed by furin. The intact prodomain released by furin alone, however, is a potent inhibitor of the emerging MT1-MMP enzyme. Evidence suggests that the prodomain undergoes intradomain cleavage at the PGD ↓ L(50) site followed by the release of the degraded prodomain by furin cleavage that finalizes the two-step activation event. These cleavages, only if combined, cause the activation of MT1-MMP. The significance of the intradomain cleavage in the protumorigenic program of MT1-MMP, however, remained unidentified. To identify this important parameter, in our current study, we used the cells that expressed the wild-type prodomain-based fluorescent biosensor and the mutant biosensor with the inactivated PGD↓L(50) cleavage site (L50D mutant) and also the cells with the enforced expression of the wild-type and L50D mutant MT1-MMP. Using cell-based tests, orthotopic breast cancer xenografts in mice, and genome-wide transcriptional profiling of cultured cells and tumor xenografts, we demonstrated that the intradomain cleavage of the PGD ↓ L(50) sequence of the prodomain is essential for the protumorigenic function of MT1-MMP. Our results emphasize the importance of the intradomain cleavages resulting in the inactivation of the respective inhibitory prodomains not only for MT1-MMP but also for other MMP family members.

Highlights

  • (MT-MMPs) are distinguished from soluble MMPs by an additional transmembrane domain and a short cytoplasmic tail (MT1, MT2, MT3, and MT5-MMP) or by a glycosylphosphatidylinositol anchor (MT4- and MT6-MMPs) [6, 7]

  • It is established that in the course of the secretion pathway of the membrane type-1 matrix metalloproteinase (MT1-MMP) proenzyme through the cell compartment the R108RKR1112Y112 prodomain sequence is processed by furin [17, 18]

  • That the intact prodomain released by furin alone is a potent inhibitor of the emerging MT1-MMP enzyme

Read more

Summary

Introduction

(MT-MMPs) are distinguished from soluble MMPs by an additional transmembrane domain and a short cytoplasmic tail (MT1-, MT2-, MT3-, and MT5-MMP) or by a glycosylphosphatidylinositol anchor (MT4- and MT6-MMPs) [6, 7]. Proteolytic removal of the N-terminal prodomain is required for the proenzyme conversion into the functionally active MT1-MMP enzyme. Furin proteolysis follows to complete both the degradation and removal of the residual prodomain sequence, transforming the activation intermediate into the mature, proteolytically active MT1-MMP enzyme commencing from the N-terminal Tyr112 [13, 21, 22]. Because of its continuing non-covalent association with the intact inhibitory prodomain, the L50D mutant enzyme appeared functionally silenced [20] These earlier biochemical studies shed light on the mechanistic aspects of MT1-MMP activation. Activation of MT1-MMP in Cancer Cells the prodomain is released by furin cleavage alone, the protumorigenic function of cellular MT1-MMP is significantly reduced in vivo

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call